Donor Batf3 inhibits murine lung allograft rejection and airway fibrosis

Mucosal Immunol. 2023 Apr;16(2):104-120. doi: 10.1016/j.mucimm.2023.02.004. Epub 2023 Feb 25.

Abstract

Chronic lung allograft dysfunction (CLAD) limits survival after lung transplantation. Noxious stimuli entering the airways foster CLAD development. Classical dendritic cells (cDCs) link innate and adaptive immunity and exhibit regional and functional specialization in the lung. The transcription factor basic leucine zipper ATF-like 3 (BATF3) is absolutely required for the development of type 1 cDCs (cDC1s), which reside in the airway epithelium and have variable responses depending on the context. We studied the role of BATF3 in a mouse minor alloantigen-mismatched orthotopic lung transplant model of CLAD with and without airway inflammation triggered by repeated administration of intratracheal lipopolysaccharide (LPS). We found that cDC1s accumulated in allografts compared with isografts and that donor cDC1s were gradually replaced by recipient cDC1s. LPS administration increased the number of cDC1s and enhanced their state of activation. We found that Batf3-/- recipient mice experienced reduced acute rejection in response to LPS; in contrast, Batf3-/- donor grafts underwent enhanced lung and skin allograft rejection and drove augmented recipient cluster of differentiation 8+ T-cell expansion in the absence of LPS. Our findings suggest that donor and recipient cDC1s have differing and context-dependent roles and may represent a therapeutic target in lung transplantation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allografts
  • Animals
  • Fibrosis
  • Graft Rejection / drug therapy
  • Lipopolysaccharides
  • Lung / pathology
  • Lung Transplantation*
  • Mice
  • Mice, Inbred C57BL
  • Pulmonary Fibrosis* / pathology
  • Transplantation, Homologous

Substances

  • Lipopolysaccharides
  • Batf protein, mouse